Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03237572
Recruitment Status : Recruiting
First Posted : August 2, 2017
Last Update Posted : January 30, 2018
Information provided by (Responsible Party):
Patrick Dillon, MD, University of Virginia

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 16, 2019
  Estimated Study Completion Date : November 25, 2021